Glaukos stock reports 50 percent Q2 revenue growth

Published on 10/05/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glaukos stock was trading at USD 163.66 on October 5 as Q2 revenue reached USD 185.6 million, up 50 percent year over year. Guidance rose to USD 680 million-USD 700 million.

GKOS, US3773221029, Illustration mit AI erstellt.

Glaukos stock (ISIN US3773221029) was trading at USD 163.66 on the NYSE on October 5, 2026, while the company enters the next reporting cycle after a 50 percent jump in second-quarter revenue. The latest quarterly update raised full-year sales guidance and put iDose TR and Epioxa at the center of the growth case.

Revenue reaches USD 185.6 million

According to Yahoo Finance in the July 29, 2026 earnings call, Glaukos reported record Q2 2026 consolidated net sales of USD 185.6 million, up 50 percent from the year-ago quarter. The finance data also show diluted GAAP EPS of negative USD 0.31 and a consolidated net loss of USD 18.4 million for the quarter ended June 30, 2026.

The revenue mix shows why the headline growth is significant. U.S. glaucoma sales reached USD 118.5 million, up 64 percent year over year, while international glaucoma sales rose 17 percent to USD 36.6 million. Corneal Health revenue increased 48 percent to USD 30.4 million, including Epioxa sales of USD 11 million, according to Yahoo Finance.

Guidance rises to USD 700 million

Management raised fiscal 2026 net sales guidance to USD 680 million-USD 700 million from USD 620 million-USD 635 million previously. The new range is USD 60 million-USD 65 million higher at the lower and upper ends, respectively, giving investors a concrete measure of the Q2 outperformance.

iDose TR generated USD 74 million in Q2, while management said full-year iDose revenue could reach USD 275 million-USD 280 million. Epioxa adds a second commercial growth driver, but the company also described a transition period around its permanent reimbursement code that may create volatility in the third quarter, according to Yahoo Finance.

Analysts see further upside

As Markets Insider reported on October 2, 2026, Stifel maintained a Buy rating and a USD 190.00 price target. The same report described a Strong Buy consensus with an average target of USD 197.33, implying 20.3 percent upside from the cited price level, while Jefferies reiterated a Buy rating with a USD 210.00 target on September 22, 2026.

The market is already pricing in a substantial growth premium. At USD 163.66 on October 5, 2026, Glaukos stock stood 14.6 percent below its 52-week high of USD 191.62, while its market capitalization was USD 9.7 billion. That gap leaves execution on guidance and the reimbursement rollout as the two clearest checkpoints for the valuation.

Glaukos stock trades at USD 163.66

Glaukos stock was trading at USD 163.66 on the NYSE on October 5, 2026 at 10:43 a.m. ET, down 0.05 percent from the prior close. The session range was USD 163.17 to USD 165.27, and volume stood at 41,175 shares.